Peptide Research Compound (Innate Repair Receptor Agonist)
Product: ARA-290 16 mg
Active Substance: ARA-290
Strength: 16 mg/vial
Container: 2 mL vial
Manufacturer: Dragon Pharma
Out of stock
Overview
Science & Research
Safety Information
FAQ
Reviews
Dragon Pharma Peptide Product
Dragon Pharma ARA-290 16 mg Overview
Dragon Pharma ARA-290 16 mg is supplied as a lyophilized powder in a 2 mL vial and contains the investigational peptide ARA-290 (cibinetide) at a labeled strength of 16 mg/vial. Product specifications, storage information, and other practical product details are provided below.
16 mg/Vial Strength
Each vial is labeled at 16 mg of ARA-290 peptide.
2 mL Vial
Supplied as a lyophilized powder in a sealed 2 mL vial.
Lyophilized Form
Supplied as a freeze-dried powder for reconstitution with bacteriostatic water or suitable diluent.
Dragon Pharma
Manufactured and packaged under the Dragon Pharma product line.
Product Specifications
Product name
ARA-290 16 mg
Active substance
ARA-290 (Cibinetide)
Labeled strength
16 mg/vial
Container
2 mL vial
Product form
Lyophilized powder
Manufacturer
Dragon Pharma
Related Products
Other peptide research products available from Dragon Pharma include BPC-157 5 mg, a peptide investigated for tissue repair, and TB-500 5 mg, a peptide related to actin regulation. Each has a distinct research profile and mechanism of action.
Science & Research
Understanding ARA-290
ARA-290 (cibinetide) is an investigational 11-amino-acid synthetic peptide derived from erythropoietin (EPO). It is designed to activate the innate repair receptor (IRR), a receptor complex that mediates tissue-protective and anti-inflammatory effects without stimulating red blood cell production.
1
EPO-Derived Peptide
ARA-290 is an 11-amino-acid peptide derived from erythropoietin that is designed to retain tissue-protective properties while avoiding erythropoietic effects.
2
Innate Repair Receptor Activation
ARA-290 activates the innate repair receptor (IRR), a heterodimeric receptor complex involved in tissue protection and repair signaling.
3
Anti-Inflammatory Activity
Research has investigated ARA-290 for its potential to reduce inflammation and neuropathic pain through IRR activation.
Mechanism of Action
ARA-290 is a synthetic 11-amino-acid peptide derived from erythropoietin (EPO) that is designed to retain the tissue-protective properties of EPO while eliminating its erythropoietic activity. The peptide activates the innate repair receptor (IRR), a heterodimeric receptor complex composed of the EPO receptor and the Ξ²-common receptor.
Activation of the IRR is thought to trigger signaling pathways involved in tissue protection, anti-inflammation, and repair processes. Unlike EPO, ARA-290 does not stimulate red blood cell production, which is a key distinction in its research profile.
Research Context
ARA-290 has been investigated in preclinical and clinical research for its potential to reduce inflammation, neuropathic pain, and tissue damage in various conditions. Its ability to activate the IRR without affecting erythropoiesis has made it a subject of research interest in inflammation and tissue repair.
Dragon Pharma ARA-290 16 mg is supplied as a lyophilized powder in a 2 mL vial at a labeled strength of 16 mg/vial.
Research References
ARA-290 has been the subject of research investigating its properties and potential applications.
ARA-290 is a research peptide with limited safety data in humans. As a compound designed to activate the innate repair receptor and modulate inflammatory pathways, its use requires careful consideration of potential physiological effects.
Cardiovascular Effects
ARA-290 may influence inflammatory and tissue repair pathways. Individuals with cardiovascular conditions should exercise caution.
Injection Site Reactions
Reconstituted peptides may cause localized reactions at the injection site. Proper aseptic technique is essential for preparation and administration.
Immune Modulation
ARA-290 may influence inflammatory responses through innate repair receptor activation. The full scope of these effects is not fully characterized.
Pregnancy and Breastfeeding
ARA-290 is not indicated for use during pregnancy or breastfeeding. Its effects on fetal development and infant health are not established.
Conditions That Require Medical Review
Medical advice is particularly important when there is a history of autoimmune conditions, inflammatory disorders, or when taking medications that may interact with inflammatory pathways.
The product should also be stored securely to prevent accidental access or use by children or other household members.
When to Seek Urgent Medical Help
Seek urgent medical attention for symptoms such as severe allergic reactions, chest pain, sudden shortness of breath, fainting, or signs of a serious adverse reaction.
Tested Sport
ARA-290 is not currently listed on the WADA Prohibited List. However, the use of peptides and research compounds may be subject to specific anti-doping rules depending on the sport and governing body. Current requirements should be checked against the relevant anti-doping rules before competition.
Quick answers about ARA-290 16 mg specifications, storage, shipping, Bitcoin payment and general product information.
What is Dragon Pharma ARA-290 16 mg?
Dragon Pharma ARA-290 16 mg is a lyophilized peptide product containing ARA-290 (cibinetide) at a labeled strength of 16 mg per vial. It is supplied in a 2 mL vial as a freeze-dried powder.
What is ARA-290?
ARA-290 (cibinetide) is an investigational 11-amino-acid synthetic peptide derived from erythropoietin. It activates the innate repair receptor (IRR) and is researched for its potential to reduce inflammation and neuropathic pain without stimulating red blood cell production.
How is ARA-290 16 mg supplied?
It is supplied as a lyophilized powder in a 2 mL vial. The product must be reconstituted with a suitable diluent such as bacteriostatic water before use in a research setting.
How does ARA-290 differ from erythropoietin (EPO)?
ARA-290 is derived from EPO but is designed to retain tissue-protective properties while eliminating erythropoietic activity. Unlike EPO, ARA-290 does not stimulate red blood cell production.
Is ARA-290 16 mg FDA approved?
No. ARA-290 is not FDA-approved for any therapeutic use. It is a research compound intended for laboratory and preclinical research purposes only.
How should ARA-290 16 mg be stored?
Keep the lyophilized powder in its original packaging and protect it from excessive heat, moisture and direct light. Refer to the product label for specific storage directions regarding temperature and shelf life. Once reconstituted, the solution should be used promptly or stored according to the manufacturer's directions.
Does ARA-290 16 mg require refrigeration?
Follow the storage instructions printed on the supplied product. Lyophilized peptides often require refrigeration, but specific storage conditions should be verified from the product label.
How long does ARA-290 16 mg delivery take?
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4β5 business days after dispatch, while shipments from the International Warehouse typically take 15β20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Can I buy ARA-290 16 mg with Bitcoin?
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy ARA-290 16 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Is Bitcoin payment anonymous?
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Is ARA-290 permitted in tested sport?
ARA-290 is not currently listed on the WADA Prohibited List. However, the use of peptides and research compounds may be subject to specific anti-doping rules depending on the sport and governing body. Current requirements should be checked against the relevant anti-doping rules before competition.
Where can I find more information about ARA-290?
Additional information about ARA-290 is available through PubMed and other research literature databases. Direct links are provided in the Science & Research section above.
